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Abstract
Background: Off‐label prescribing is encountered across various fields of medicine and
creates alternative treatment options, but is associated with unknown safety risks. The
use of off‐label drugs for the treatment of patients with inflammatory bowel diseases
(IBD) has not been characterised before.
Aim: To assess the proportion and characteristics of off‐label prescribing for IBD in ter-
tiary care centres in the Netherlands.
Methods: A prospective database of IBD patients from all Dutch university hospitals
was used to collect data on drug prescriptions for IBD and demographics. Drugs were
classified as off‐label if they were unlicensed for Crohn's disease and/or ulcerative colitis
by the Medicines Evaluation Board. Uni‐ and multivariable analyses were used to identify
patient‐specific characteristics predictive of increased off‐label use.
Results: For the induction and/or maintenance treatment of 4583 IBD patients, 12 651
historical and current drug records were available in the database. Of these, 2374 (19%)
were considered off‐label prescriptions. Out of 4583 IBD patients, 1477 (32%) were
exposed to off‐label drugs. Commonly prescribed off‐label IBD drugs were mercaptop-
urine (18%), beclomethasone (12%), thioguanine (4%) and allopurinol (3%). Non‐thiop-
urine/methotrexate off‐label drugs were prescribed in 243 patients (6%), including
biological agents or tofacitinib in 47 IBD patients (1%). Off‐label prescriptions were more
common in ulcerative colitis than Crohn's disease (37% vs 29%, P < 0.001). Smokers and
patients that received ≥5 drug types during their disease course were more likely to be
exposed to off‐label drugs (smoking 33% vs 27% and multiple drug use 66% vs 22%,
both P < 0.001).
Conclusion: About one‐fifth of prescriptions for IBD were off‐label and one‐third of
IBD patients, especially ulcerative colitis patients, were exposed to off‐label drugs.
The Handling Editor for this article was Professor Jonathan Rhodes, and it was accepted for
publication after full peer‐review.
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1 | INTRODUCTION
Off‐label drug prescribing is widespread in daily clinical practice and
includes the use of drugs outside the licensed indication, dosage,
route of administration or age.1 Examples of widely prescribed off‐la-
bel drugs include the use of beta‐blockers for anxiety, tricyclic
antidepressants for chronic pain and oral contraception to treat
endometriosis or acne.
Off‐label drugs may create alternative therapeutic options, but
have also been associated with safety risks since they are under‐
evaluated for unlicensed indications.2 A lack of drug approval by the
Food and Drug Administration (FDA) or the European Medicines
Agency (EMA) generally means a shortage of scientific scrutiny as
compared to labelled indications.3 In a large Canadian cohort, the
rate of preventable adverse drug reactions was considerably higher
in off‐label prescriptions (19.7 per 10 000 person‐months) as com-
pared to on‐label prescriptions (12.5 per 10 000 person‐months).2
Although off‐label prescribing is legal and common in most coun-
tries, physicians carry primary responsibility for accurately prescrib-
ing and monitoring therapy with off‐label drugs, as acknowledged by
the Medicines Healthcare product Regulatory Agency (MHRA) and
the General Medical Council (GMC) in the United Kingdom (UK).4,5
Several studies reported on the inadequate awareness of off‐label
drugs by physicians and patients. In a survey among 600 physicians
in the US, 45% was unaware of the FDA status of the medications
they prescribed.6 In a teaching hospital in India, two‐thirds of the
residents had insufficient knowledge on unlicensed drugs, and one‐
third assumed that off‐label prescribing was not legal.7
The use of off‐label drugs seems to vary between different fields
of medicine. In the intensive care unit and paediatrics, off‐label pre-
scription rates were up to 36% and 62%, respectively.8,9 In oncology,
off‐label drug prescriptions were in the range of 18%‐41% for hospi-
talised cancer patients and 7%‐50% for ambulatory care patients.10
In the largest cohort study among office‐based physicians, an esti-
mated 21% of overall prescriptions (725 million) were off‐label.11
In the treatment of inflammatory bowel diseases (IBD), off‐label
drugs are prescribed as well, especially in patients who failed stan-
dard treatment regimens. The overall magnitude of off‐label prescrib-
ing for Crohn's disease and ulcerative colitis is unknown. To provide
optimal therapeutic care, a better understanding of off‐label drug
prescriptions in this field is needed. We aimed to assess the propor-
tion and characteristics of off‐label prescribing for IBD.
2 | METHODS
2.1 | Study design and population
We performed a retrospective analysis of prospectively collected
data from the Dutch IBD Biobank. This is a nationwide biobank in
which data and biomaterial of adult IBD patients are routinely col-
lected from all seven Dutch university medical centres in the Nether-
lands since 2007 (ie Erasmus Medical Centre, Leiden University
Medical Centre, Maastricht University Medical Centre, Radboud
University Nijmegen Medical Centre, University Medical Centre
Groningen, University Medical Centre Utrecht and Amsterdam
University Medical Centre (locations VU University Medical Centre
and Academical Medical Centre). The Dutch IBD Biobank is part of
the Parelsnoer Institute (PSI) (www.parelsnoer.org) and is initiated
and maintained by the Initiative on Crohn's and Colitis (ICC) working
party from the Netherlands.12
All adult patients enrolled in the Dutch IBD Biobank with avail-
able data on current and historical drug prescriptions for the treat-
ment of IBD were included in the study. Duplications were excluded
from the analysis. When it was uncertain whether the unapproved
drug was prescribed for IBD or another indication, this prescription
was excluded from the off‐label analysis as well.
2.2 | Off‐label drugs
Drugs which were unlicensed for Crohn's disease and/or ulcerative
colitis by the Dutch Medicines Evaluation Board (MEB) were classi-
fied as off‐label.13,14 These off‐label drugs are depicted in Table 1.
Patients with IBD unclassified or IBD indeterminate were included in
the ulcerative colitis group, or in case of a re‐classification during the
disease course, in the group according to the most recent IBD diag-
nosis. Drugs used in addition to the primary IBD medications, for
example supplements or medication for symptom management, were
disregarded from the analysis. This also included antibiotics, because
we could not identify the precise indications for antibiotic treatment
in the nationwide IBD database. In the Netherlands, thioguanine, an
alternative thiopurine‐derivative, has been conditionally licensed as a
certified IBD treatment since mid‐2015.15 Because thioguanine was
relicensed recently and solely in the Netherlands, we considered this
drug off‐label for this study.
2.3 | Data collection
Outcome measures were (a) the proportion of IBD patients exposed to
off‐label drugs and (b) the rate of off‐label drug prescriptions for IBD.
Collected data included patient demographics, IBD phenotype accord-
ing to Montreal classification,16 disease duration, surgical history,
smoking habits and current and historical drug prescriptions for IBD.
2.4 | Statistics
Data were presented as numbers with percentages, means with
standard deviations (SD), or medians with interquartile range (IQR),
according to their distribution. Demographics and clinical characteris-
tics between off‐label users and non‐users were compared using the
Mann‐Whitney U test or the independent samples t test for continu-
ous variables and the Pearson chi‐square test or the Fisher's exact
test for categorical variables. Multivariable logistic regression models
were built to identify clinical characteristics predictive of increased
off‐label use, using a backward selection procedure with p‐removal
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set to 0.05. Results of these models are presented with odds ratios
(OR) and 95% confidence intervals (CI). Statistical analyses were per-
formed using SPSS Statistics (version 22.0; IBM Corp, Armonk, NY).
Two‐tailed probability (P)‐values <0.05 were considered statistically
significant.
2.5 | Ethical approval
This study was approved by the ICC PSI‐IBD scientific board. All
patients included in the Dutch IBD Biobank have given written
informed consent.
3 | RESULTS
3.1 | Population characteristics
In April 2018, the Dutch IBD Biobank consisted of 4810 patients. Of
these, 227 patients (5%) were excluded due to missing data on his-
torical or current drug records. The remaining 4583 patients with
available data on drug records were included in the analysis. A total
of 2702 patients (59%) were females, 2826 (62%) had Crohn's dis-
ease and 1757 patients (38%) ulcerative colitis. The median age at
time of diagnosis was 26 years (IQR 20 ‐ 37) and the median IBD
disease duration was 18 years (IQR 11 ‐ 27).
Out of 4583 IBD patients, 1477 (32%) were treated with ≥1 off‐
label drug(s) for the treatment of Crohn's disease and/or ulcerative
colitis. A total of 345 patients (8%) were treated with at least two
off‐label drugs for IBD. The patient and disease characteristics of the
IBD patient population with and without off‐label prescriptions for
Crohn's disease or ulcerative colitis are depicted in Table 2.
3.2 | Patient characteristics
There was no difference in gender ratio between patients with
(n = 1477) and without (n = 3106) off‐label prescriptions for the
treatment of IBD (Table 2). Off‐label drug users were slightly older
at time of diagnosis (30 ± 13 vs 29 ± 13, P = 0.019) and had a
shorter median IBD disease duration (16, IQR: 10 ‐ 24 vs 18, IQR:
12 ‐ 27), P < 0.001). In addition, patients who never smoked were
less exposed to off‐label drugs as compared to patients who were
previous or current smokers (27% vs 33%, P < 0.001). These out-
comes were similar for both ulcerative colitis and Crohn's disease.
3.3 | Disease characteristics
Use of off‐label drugs was higher in patients with ulcerative colitis
compared to Crohn's disease (37% vs 29%, P < 0.001). Both for
ulcerative colitis and Crohn's disease, there were no phenotypic dif-
ferences according to the Montreal classification between patients
with and without off‐label IBD prescriptions. Furthermore, there
were no differences in the number of IBD‐related surgeries including
pouch rates between off‐label drug users and non‐users. The rates
of stoma, however, were higher in the IBD group without off‐label
drug exposure (10% vs 7%, P = 0.001).
3.4 | Off‐label drugs
A total of 12 651 historical and current drug records for the induc-
tion or maintenance treatment of 4583 IBD patients were available
in the database. Of these, 2374 (19%) considered prescriptions
which were off‐label for Crohn's disease and/or ulcerative colitis. The
prevalence of the prescribed off‐label drugs for Crohn's disease and
ulcerative colitis are summarised in Figure 1.
Overall, the most commonly prescribed off‐label drugs for IBD in
the whole cohort were mercaptopurine (822/4583, 18%) and
beclomethasone (529/4583, 12%). Furthermore, thioguanine was
prescribed in 168 (4%) and allopurinol in 149 patients (3%).
Methotrexate, an immunomodulator which is only off‐label for the
treatment of ulcerative colitis, was prescribed in 71 patients (2%).
Other less traditional (non‐thiopurine/methotrexate) off‐label
drugs for the treatment of Crohn's disease or ulcerative colitis were
prescribed in 243 patients (6%). The patient and treatment charac-
teristics of this specific group are depicted in Table 3. These off‐label
immunosuppressant drugs were ciclosporin, prescribed in 105 (2%),
tacrolimus in 85 (2%), mycophenolate mofetil in 25 (0.5%) and
TABLE 1 Overview of off‐label drugs used as induction or
maintenance treatment for IBD in the Netherlands
Drug name Class of drug
Off‐label
in UC
Off‐label
in CD
Beclomethasone Steroids Yes Yes
Mercaptopurine Purine‐derivative Yes Yes
Allopurinol Purine‐derivative Yes Yes
Thioguanine Purine‐derivative Yesa Yesa
Cladribine Purine‐derivative Yes Yes
Methotrexate Folate antagonist Yes No
Ciclosporin Calcineurin inhibitor Yes Yes
Tacrolimus Calcineurin inhibitor Yes Yes
Mycophenolate IMPD inhibitor Yes Yes
Thalidomide Thalidomide analogues Yes Yes
Tofacitinib JAK inhibitor Yesb Yesb
Ustekinumab Biological agent Yes No
Golimumab Biological agent No Yes
Certolizumab Biological agent Yes Yes
Natalizumab Biological agent Yes Yes
Rituximab Biological agent Yes Yes
Etanercept Biological agent Yes Yes
CD: Crohn's disease; IBD: inflammatory bowel disease; IMPD: inosine
monophosphate dehydrogenase; JAK: Janus kinase; UC: ulcerative colitis.
aThioguanine is licensed for CD and UC conditionally and solely in the
Netherlands since April 2015. It was considered off‐label for this retro-
spective analysis.
bTofacitinib is licensed for UC in the Netherlands since July 2018. It was
considered off‐label for this retrospective analysis.
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thalidomide in 12 IBD patients (0.2%). Off‐label targeted
immunomodulators, ie biological agents or Janus kinase (JAK) inhibi-
tors, were prescribed in 45 Crohn's disease patients and included
certolizumab in 21 (0.5%), golimumab in 15 (0.3%), natalizumab in six
(0.1%) and tofacitinib in two patients (0.04%). Furthermore, two
patients (0.04%) with ulcerative colitis received off‐label treatment
with ustekinumab.
If we considered mercaptopurine as the standard of care and on‐
label for IBD, in line with the international guidelines, the population
that received ≥1 off‐label drug(s) decreased to 984 patients (984/
4583, 21%). The rate of off‐label prescriptions for IBD decreased to
1512 out of 12 651 prescriptions (12%).
3.5 | Multiple drug use (≥ 5) during IBD course
Patients who used multiple drugs during their IBD disease course,
defined as at least five different drugs, were more likely to receive
off‐label drugs (66% vs 22%, P < 0.001). This association appeared
to be stronger in ulcerative colitis (69% of patients with multiple
drug use were treated with off‐label drugs) than in Crohn's disease
TABLE 2 Patient and disease characteristics of 4583 IBD patients
Patients with off‐label drugs Patients without off‐label drugs P‐value
Number of patients 1477 (32%) 3106 (68%)
Sex, female 887 (60%) 1815 (58%) 0.30
Age at diagnosis, yr 30 ± 13 29 ± 13 0.019
IBD disease duration, yr 16 (10‐24) 18 (12‐27) <0.001
Smoking (available data) 1191 (80%) 2759 (89%) <0.001
Yes 733 (62%) 1505 (55%)
No 458 (38%) 1254 (45%)
Crohn's disease 831 (56%) 1995 (64%)
Montreal: Age at diagnosis (available data) 809 (97%) 1894 (95%) 0.89
<17 (A1) 82 (10%) 213 (11%)
17‐40 (A2) 603 (75%) 1383 (73%)
>40 (A3) 124 (15%) 298 (16%)
Montreal: Behaviour (available data) 831 (100%) 1995 (100%) 0.94
Non‐stricturing, non‐penetrating (B1) 487 (59%) 1133 (57%)
Stricturing (B2) 216 (26%) 545 (27%)
Penetrating (B3) 128 (15%) 317 (16%)
Perianal disease (+P) 224 (27%) 511 (26%) 0.27
Montreal: Location (available data) 667 (80%) 1490 (75%) 0.55
Ileal (L1) 139 (21%) 338 (23%)
Colonic (L2) 206 (31%) 447 (30%)
Ileocolonic (L3) 259 (39%) 546 (37%)
Upper GI‐disease (+L4) 63 (9%) 159 (11%)
Ulcerative colitis 646 (44%) 1111 (36%)
Montreal: Extent (available data) 483 (75%) 814 (73%) 0.29
Proctitis (E1) 80 (16%) 151 (19%)
Left‐sided (E2) 134 (28%) 246 (30%)
Pancolitis (E3) 269 (56%) 417 (51%)
Resection 311 (21%) 611 (20%) 0.28
Small bowel 135 (43%) 283 (46%)
Large bowel 114 (37%) 179 (29%)
Small and large bowels 59 (19%) 142 (23%)
Pouch 59 (4%) 108 (3%) 0.38
Stoma 107 (7%) 314 (10%) 0.001
Multiple drug use (≥5) 968 (66%) 682 (22%) <0.001
IBD: inflammatory bowel disease; GI: gastrointestinal; yr: year.
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(53% of patients with multiple drug use were treated with off‐label
drugs).
3.6 | Determinants of off‐label prescribing
Several determinants were associated with increased off‐label pre-
scribing as presented in Table 4. Being diagnosed with ulcerative col-
itis (OR: 1.54, 95 CI%: 1.30‐1.82), smoking (OR 0.80, 95 CI%: 0.68‐
0.94), shorter IBD disease duration (OR: 0.99, 95 CI%: 0.98‐0.99),
bowel resection (OR: 0.77, 95 CI%: 0.64‐0.94) and exposure to ≥ 5
types of drugs during the disease course (OR: 0.15, 95 CI%: 0.13‐
0.18) were predictive of off‐label drug exposure. Age at diagnosis
and having a stoma were not predictive for off‐label drug use any
more in this multivariable model. Gender and other specific disease
characteristics, such as IBD phenotype and having a pouch, were
again not associated with off‐label drug use.
4 | DISCUSSION
In this nationwide IBD cohort of all Dutch university hospitals, 32%
of patients were exposed to off‐label drugs and 19% of all prescrip-
tions were off‐label. Patients with ulcerative colitis were more likely
to receive off‐label drugs compared to patients with Crohn's disease.
Off‐label prescriptions were also more common among smokers (in
both Crohn's disease and ulcerative colitis) and patients who
received at least 5 different drugs for IBD during their disease
course. Age at diagnosis and having a stoma were only associated
with off‐label drugs in the univariate analyses.
Off‐label prescribing is encountered across various fields of med-
icine. Unlike FDA or EMA labelled drugs, off‐label drugs may lack
scientific evidence and be associated with safety risks considering
that they are under‐evaluated for the unapproved indication.2
Accountable use of (off‐label) medicines has received growing atten-
tion in recent years. Also in the Netherlands, regulations for off‐label
prescriptions are more strictly regulated by the Dutch Medicines Act
since 2007 due to safety concerns.17 The regulations of off‐label
prescribing are not harmonised across the world. Even in Europe,
each country has established its own regulations.18 Comparing
results on off‐label prescribing between countries is therefore diffi-
cult, but the need of better understanding and proper prescribing of
off‐label drugs has been universally acknowledged.
In this Dutch cohort, mercaptopurine was the most frequently
prescribed off‐label drug for IBD. Although not formally approved in
the Netherlands, mercaptopurine is a globally established treatment
option for IBD. Compared to most off‐label drugs which lack exten-
sive clinical evidence for its use, toxicity and benefit of mercaptop-
urine for IBD have been broadly studied. Azathioprine, on the other
hand, has been a certified IBD treatment option in the Netherlands,
but it is not superior to mercaptopurine in literature.19,20 Hence off‐
label drugs are not necessarily associated with shortage of scientific
evidence as compared with licensed drugs and may be even consid-
ered as standard of care. In case that mercaptopurine was recog-
nised as an on‐label drug for IBD in the Netherlands, the proportion
of patients receiving off‐label drugs and the rate of off‐label pre-
scriptions in this population would have decreased to 21% and 12%,
respectively.
Thioguanine, a less‐established thiopurine‐derivative, was pre-
scribed in 4% of all patients in this cohort. After being utilised as an
off‐label drug for IBD for years, thioguanine has been recently
licensed conditionally for IBD in the Netherlands.15 The relicensing
of thioguanine was considered unique and important to accomplish
safe application of this drug in IBD patients who previously failed
azathioprine or mercaptopurine. Prospective registry studies are
ongoing to gather additional data on efficacy and safety of thiogua-
nine as a maintenance treatment for IBD before final evaluation.21
Other frequently prescribed off‐label drugs in this IBD cohort
included beclomethasone (12%), ciclosporin (2%) and tacrolimus (2%).
Also considering these drugs, robust safety databases might be
important to adequately determine the benefit‐risk profile of these
off‐label therapies for the treatment of patients with IBD.
We observed a total rate of 19% off‐label prescriptions for IBD
in this nationwide cohort. This proportion is consistent with the lar-
gest cohort study of Radley et al11 in which an estimated 21% of
overall prescriptions (725 million) written by office‐based physicians
were off‐label. In both their and our study, off‐label prescriptions did
not include use of drugs through an unapproved route of administra-
tion, dosage or treatment duration. A wider definition of off‐label
drug use may have increased the proportion of off‐label drug use in
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F IGURE 1 Prevalence rates of off‐label drug use in Crohn's
disease and ulcerative colitis (n = 4583). Bar chart shows the
prevalence of prescriptions per each off‐label drug among the
inflammatory bowel disease population (n = 4583). Prevalence rates
of each bar are split into ulcerative colitis (UC) and Crohn's disease
(CD)
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TABLE 3 IBD patients treated with off‐label, non‐conventional immunomodulating drugs
Ciclosporin Tacrolimus Mycophenolate Thalidomide Certolizumab Golimumab Natalizumab Tofacitinib Ustekinumab
Total N of patients 105 85 25 12 21 15 6 2 2
Crohn's disease 45 (43%) 26 (31%) 16 (64%) 9 (75%) 21 (100%) 15 (100%) 6 (100%) 2 (100%)
Sex, female 33 (73%) 18 (69%) 11 (69%) 7 (78%) 18 (86%) 10 (67%) 6 (100%) 2 (100%)
Age at diagnosis,
yr
26 ± 9 29 ± 14 28 (15 ‐ 72) 27 (11 ‐ 60) 22 (14 ‐ 31) 26 (14 ‐ 50) 25 (20 ‐ 34) 13 (9 ‐ 17)
IBD disease duration,
yr
25 (6 ‐ 54) 14 (6 ‐ 38) 23 (4 ‐ 39) 26 (13 ‐ 54) 19 (3 ‐ 40) 15 (3 ‐ 30) 22 (12 ‐ 27) 26 (17 ‐ 34)1
Treatment duration,
mo.
4 (1 ‐ 38) 5 (1 ‐ 24) 11 (3 ‐ 38) 7 (2 ‐ 80) 16 (12 ‐ 32) 23 (3 ‐ 60) 69 (60 ‐ 78) 20 (15 ‐ 24)
Resection 9 (20%) 8 (31%) 13 (81%) 4 (44%) 12 (57%) 8 (53%) 1 (17%) 0 (0%)
Multiple drug use
(≥5)
39 (87%) 25 (96%) 16 (100%) 9 (100%) 19 (91%) 9 (60%) 6 (100%) 2 (100%)
Montreal: Age at
diagnosis
<17 (A1) 4 (9%) 3 (11%) 1 (6%) 3 (33%) 3 (14%) 2 (13%) 6 (100%) 1 (50%)
17‐40 (A2) 37 (82%) 18 (69%) 12 (75%) 5 (56%) 17 (81%) 10 (67%) 0 (0%) 1 (50%)
>40 (A3) 4 (9%) 5 (19%) 3 (19%) 1 (11%) 1 (5%) 3 (20%) 0 (0%) 0 (0%)
Montreal:
Behaviour
Non‐stricturing,
non‐penetrating (B1)
26 (58%) 17 (65%) 8 (50%) 5 (56%) 11 (52%) 10 (67%) 0 (0%) 0 (0%)
Stricturing (B2) 9 (20%) 1 (4%) 5 (31%) 2 (22%) 4 (19%) 3 (20%) 4 (67%) 1 (50%)
Penetrating (B3) 10 (22%) 8 (31%) 3 (19%) 2 (22%) 6 (29%) 2 (13%) 2 (33%) 1 (50%)
Perianal disease
(+P)
15 (33%) 8 (31%) 7 (44%) 3 (33%) 12 (57%) 5 (33%) 6 (100%) 1 (50%)
Montreal: Location
Ileal (L1) 4 (10%) 2 (10%) 1 (6%) 1 (11%) 4 (19%) 2 (13%) 0 (0%) 0 (0%)
Colonic (L2) 11 (28%) 6 (30%) 3 (19%) 2 (22%) 4 (19%) 2 (13%) 3 (50%) 1 (50%)
Ileocolonic (L3) 22 (56%) 11 (55%) 12 (75%) 5 (56%) 11 (52%) 9 (60%) 2 (33%) 1 (50%)
Upper GI‐disease
(+L4)
3 (8%) 1 (5%) 0 (0%) 1 (11%) 2 (10%) 0 (0%) 1 (17%) 0 (0%)
Ulcerative colitis 60 (57%) 59 (69%) 9 (36%) 3 (25%) 2 (100%)
Sex, female 30 (50%) 37 (63%) 5 (56%) 0 (0%) 2 (100%)
Age at diagnosis, yr 29 ± 12 35 ± 15 17 (9‐59) 47 (32‐61) 62 (55‐68)
IBD disease duration,
yr
17 (6‐54) 14 (2‐51) 13 (7‐38) 15 (10‐20) 5 (4‐6)
Treatment duration,
mo.
5 (1‐38) 6 (1‐32) 12 (3‐244) NA 32 (11‐53)
Resection 11 (18%) 11 (19%) 2 (22%) 0 (0%) 0 (0%)
Multiple drug use
(≥5)
48 (80%) 47 (80%) 9 (100%) 2 (67%) 2 (100%)
Montreal: Extent
Proctitis (E1) 3 (6%) 14 (29%) 0 (0%) 0 (0%) 0 (0%)
Left‐sided (E2) 17 (36%) 10 (20%) 3 (33%) 0 (0%) 2 (100%)
Pancolitis (E3) 27 (58%) 25 (51%) 6 (67%) 3 (100%) 0 (0%)
IBD: inflammatory bowel disease; GI: gastrointestinal; mo: months; NA: not available; yr: year.
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our cohort, however, we were unable to account for these drug
characteristics. In the field of paediatrics, off‐label prescription rates
are considerable higher and rates go up to 80%.22 Including the pae-
diatric IBD population to our cohort would most likely have
increased the proportion of off‐label prescriptions substantially.
In this study, we explored a poorly studied aspect of therapeutic
IBD care using a nationwide database to provide an insight into off‐
label prescribing for IBD. Our tertiary care population represents
patients with complicated diseases who may have been at increased
risk for being treated with drugs outside of the standard treatment
regimen. Therefore, generalisation of these findings to the broader
IBD population is not prudent. Another limitation of our study was
that we strongly depend on the strength of data documentation at
the site level. The information in the Dutch IBD Biobank is updated
regularly (ie data are automatically uploaded from the local database
to the central database at least once a month), still missing data or
information bias might have been introduced in our study.12 More-
over, we only investigated the prevalence of off‐label IBD prescrip-
tions and the proportion of patients exposed to these drugs, but we
were not able to assess further questions about the reasons for initi-
ation and withdrawal of off‐label drugs. Future research is needed to
evaluate the considerations for, and knowledge about, off‐label pre-
scriptions and its safety and consequences for the treatment of IBD.
Another interesting issue would be the impact of costs of off‐label
prescriptions, as compared to novel costly pharmaceutical agents, on
the treatment of IBD.
In conclusion, in a nationwide cohort consisting of tertiary IBD
patients, about one‐third was exposed to off‐label drugs and one‐
fifth of all IBD prescriptions were off‐label. Off‐label drug use was
more common among patients with ulcerative colitis, smokers and
patients who previously received at least five different IBD drugs
during their disease course.
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TABLE 4 Predictive factors for off‐label drug use in IBD patients
Determinants OR 95% CI P‐value
IBD disease duration (per year) 0.99 0.98 ‐ 0.99 <0.001
IBD diagnosis
Crohn's disease 1
Ulcerative colitis 1.54 1.30 ‐ 1.82 <0.001
Smoking
Yes 1
No 0.80 0.68 ‐ 0.94 0.007
Resection
Yes 1
No 0.77 0.64 ‐ 0.94 0.011
Multiple drug use (≥5)
Yes 1
No 0.15 0.13 ‐ 0.18 <0.001
CI: confidence intervals; IBD: inflammatory bowel disease; OR: odds
ratio.
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